Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference
Contineum Therapeutics (NASDAQ:CTNM) had its price target lowered by analysts at Robert W. Baird from $16.00 to $14.00. They now have an "outperform" rating on the stock.
Contineum Therapeutics (NASDAQ:CTNM) had its price target lowered by analysts at Royal Bank Of Canada from $25.00 to $22.00. They now have an "outperform" rating on the stock.
Contineum falls after missing main goals in multiple sclerosis trial [Seeking Alpha]
Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) [Yahoo! Finance]